MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$267,949K
Net Income
-$114,646K
Net Profit Margin
-42.79%
EPS
-$0.69
Unit: Thousand (K) dollars
Revenue Breakdown
Collaborative Agreement Revenue
Spinraza Royalties
DAWNZERASales
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Revenue
267,949
246,091
156,719
452,049
Cost of sales
2,739
2,983
2,338
4,151
Research, development and patent
217,107
210,173
217,754
217,460
Selling, general and administrative
150,396
150,359
96,809
90,622
Total operating expenses
370,242
363,515
316,901
312,233
Income (loss) from operations
-102,293
-117,424
-160,182
139,816
Investment income
20,230
25,484
23,682
24,687
Interest expense
4,618
5,160
4,212
4,114
Interest expense related to sale of future royalties
17,506
17,337
17,952
18,648
Gain (loss) on investments, net
-10,182
22,583
29,908
-18,312
Other income, net
987
-456
363
102
Income (loss) before income tax benefit (expense)
-113,382
-92,310
-128,393
123,531
Income tax benefit (expense)
1,264
218
213
-20
Net income (loss)
-114,646
-92,528
-128,606
123,551
Basic EPS
-0.69
-0.56
-0.8
0.78
Diluted EPS
-0.69
-0.56
-0.8
0.7
Basic Average Shares
165,419,000
164,874,000
159,765,000
159,137,000
Diluted Average Shares
165,419,000
164,874,000
159,765,000
182,331,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Spinraza Royalties
$53,486K
(-1.57%↓ Y/Y)
Wainus Royalties
$16,436K
(57.81%↑ Y/Y)
Other Royalties
$6,036K
(16.08%↑ Y/Y)
DAWNZERASales
$26,565K
Tryngolza
$4,574K
(-76.27%↓ Y/Y)
Net income (loss)
-$114,646K
(-192.79%↓ Y/Y)
Collaborative Agreement
Revenue
$133,137K
(-60.48%↓ Y/Y)
Wainua Joint
Development Revenue
$16,189K
(30.85%↑ Y/Y)
Royalty
$75,958K
(8.59%↑ Y/Y)
Product
$31,139K
(61.57%↑ Y/Y)
Other Commercial
$11,526K
(-14.82%↓ Y/Y)
Income (loss) before
income tax benefit...
-$113,382K
(-191.78%↓ Y/Y)
Income tax benefit
(expense)
$1,264K
(6420.00%↑ Y/Y)
Investment income
$20,230K
(-18.05%↓ Y/Y)
Research And Development
Revenue
$149,326K
(-57.25%↓ Y/Y)
Commercial
$118,623K
(15.44%↑ Y/Y)
Other income, net
$987K
(867.65%↑ Y/Y)
Income (loss) from
operations
-$102,293K
(-173.16%↓ Y/Y)
Interest expense related
to sale of future...
$17,506K
(-6.12%↓ Y/Y)
Revenue
$267,949K
(-40.73%↓ Y/Y)
Gain (loss) on
investments, net
-$10,182K
(44.40%↑ Y/Y)
Interest expense
$4,618K
(12.25%↑ Y/Y)
Total operating
expenses
$370,242K
(18.58%↑ Y/Y)
Research, development and
patent
$217,107K
(-0.16%↓ Y/Y)
Selling, general and
administrative
$150,396K
(65.96%↑ Y/Y)
Cost of sales
$2,739K
(-34.02%↓ Y/Y)
Buy us a coffee
IONIS PHARMACEUTICALS INC (IONS)
IONIS PHARMACEUTICALS INC (IONS)